Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.173
Buy
RSI(14)
61.151
Neutral
STOCH(KDJ)(9,3,3)
72.766
Buy
ATR(14)
3.588
Low Volatility
CCI(14)
130.668
Buy
Williams %R
10.881
Overbought
TRIX(12,20)
0.204
Sell
StochRSI(14)
100.000
Buy
Search
Merck & Co Inc
MRKAdd to Watchlist
130.485USD
+3.015+2.37%
Close 07-23 16:00（ET）Quotes delayed by 15 min
322.90BMarket Cap
36.58P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+2.37%
5 Days
+2.24%
1 Month
+9.10%
6 Months
+20.62%
Year to Date
+23.96%
1 Year
+55.38%
Key Figures
127.360Open
131.040High
8.53MVolume
36.58P/E TTM
13.65P/E Dynamic
3.320Dividend TTM
0.34%Turnover Ratio
127.470Prev. Close
127.360Low
569.33MTurnover
18.86P/E Static
6.14P/B
2.54%Div Yield TTM
7.33%ROA
125.14052wk High
0.86Volume Ratio
17.12BNet Profit
2.47BShares
3.5675EPS TTM
0.22Beta
18.97%ROE
75.40052wk Low
2.89%Amplitude
75.70%Gross Margin
322.90BMarket Cap
3.67Reward/Risk
1.55%Risk Rate
TradingKey Stock Score of Merck & Co Inc
Currency: USD Updated: 2026-07-23Key Insights
Merck & Co Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 131.92.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Merck & Co Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
48°C
Very Low
Very High
Positive+
Merck & Co Inc Highlights
StrengthsRisks
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 65.01B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 46.40%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 46.40%.
Fairly Valued
The company’s latest PE is 36.57, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.01B shares, decreasing 0.52% quarter-over-quarter.
Held by Bill Smead
Star Investor Bill Smead holds 2.47M shares of this stock.
Analyst Rating
Based on
32
analysts
Buy
Current Rating
131.916
Target Price
+4.48%
Upside Space
Earnings Forecast
Analyst Rating
Based on
32
analysts
Buy
Current Rating
131.916
Target Price
+4.48%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Merck & Co Inc
MRK
32
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
127.222
Buy
MA10
125.570
Buy
MA20
126.466
Buy
MA50
120.725
Buy
MA100
118.522
Buy
MA200
110.278
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Merck & Co Inc Info
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
Ticker SymbolMRK
CompanyMerck & Co Inc
CEODavis (Robert M)
Websitehttps://www.merck.com/
Shareholders
Related Instruments
+1.95%
+1.46%
-0.85%
+1.43%
+2.01%
+1.49%
+0.38%
0.00%
+0.71%
+1.27%
+0.15%
-0.94%
-0.03%
+1.31%
0.00%
+0.11%
+8.61%
-0.21%
+2.45%Popular Instruments
FAQs
What is the current price of Merck & Co Inc (MRK)?
The current price of Merck & Co Inc (MRK) is 130.49.
What is the symbol of Merck & Co Inc?
The ticker symbol of Merck & Co Inc is MRK.
What is the 52-week high of Merck & Co Inc?
The 52-week high of Merck & Co Inc is 125.14.
What is the 52-week low of Merck & Co Inc?
The 52-week low of Merck & Co Inc is 75.40.
What is the market capitalization of Merck & Co Inc?
The market capitalization of Merck & Co Inc is 322.90B.
Is Merck & Co Inc (MRK) currently rated as Buy, Hold, or Sell?
According to analysts, Merck & Co Inc (MRK) has an overall rating of Buy, with a price target of 131.92.
What is the Earnings Per Share (EPS TTM) of Merck & Co Inc (MRK)?
The Earnings Per Share (EPS TTM) of Merck & Co Inc (MRK) is 7.30.